Clinical Trial

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe hepatic impairment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-29.
Status change: Recruiting → Completed 2026-05-07
Trial Details
NCT Number NCT06952634
Lead Sponsor Alumis Inc
Conditions Hepatic Impairment
Enrollment 32 participants
Start Date 2025-04-29
Primary Completion 2026-03-24 (estimated)
Study Completion 2026-03-24 (estimated)
Updated on ClinicalTrials.gov 2026-05-12